Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2003, for Bioanalytical Systems, Inc. (BASi). The company provides laboratory services, consulting, and research related to analytical chemistry, as well as manufacturing scientific instruments for trace organic compound determination. The filing notes that the registrant is currently known as Bioanalytical Systems, Inc., though the request metadata references "Inotiv, Inc." (a later name change).
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2003 | Six Months Ended Mar 31, 2003 |
|---|---|---|
| Total Revenue | $6,950,000 | $13,924,000 |
| Net Income (Loss) | $(167,000) | $108,000 |
| Operating Income (Loss) | $(147,000) | $322,000 |
| Gross Profit | $2,257,000 | $4,942,000 |
| Cash and Equivalents | $889,000 (as of Mar 31, 2003) | |
| Net Cash from Operating Activities | $254,000 (Six Months) | |
| Total Debt (Current + Long-Term) | ~$13.4M (Includes revolving credit, construction loans, and subordinated debt) |
Margins: Gross margin for the three months ended March 31, 2003, was approximately 32.5%. Service revenue cost of goods sold increased to 81.5% of service revenue for the quarter, up from 65.8% in the prior year.
Material Changes vs. Prior Period
- Revenue Decline (Quarterly): Total revenue decreased 5.9% to $6.95 million compared to $7.39 million in the prior year quarter. This was driven by a 24% drop in product revenue (due to lower Culex unit sales), partially offset by a 7.5% increase in service revenue.
- Revenue Growth (Six Months): Total revenue increased 3.9% to $13.92 million compared to the prior year six-month period, driven by a 16.4% increase in service revenue.
- Profitability: The company reported a net loss of $167,000 for the quarter, compared to net income of $519,000 in the prior year quarter. Operating income turned negative ($147,000 loss) from a $795,000 profit in the prior year.
- Cost Increases: Total cost of revenue increased 10.7% for the quarter, primarily due to costs associated with the acquisition of LC Resources, Inc. and increased bioanalytical service costs in the UK.
- Acquisition Impact: BASi acquired LC Resources, Inc. in December 2002. The acquisition added goodwill of $1.35 million and increased service costs.
Guidance, Outlook, and Risks
- Guidance Withdrawn: Management previously estimated fiscal 2003 revenues at approximately $40 million. This has been revised down to approximately $30 million. Management has determined it will no longer provide financial guidance due to multiple variables and uncertainties.
- Acquisition Delays: Delays in closing the merger with PharmaKinetics Laboratories, Inc. (PKLB) and the acquisition of LC Resources prevented the inclusion of anticipated revenues and operational improvements in the current fiscal year.
- Liquidity and Debt: The company has significant debt obligations, including a $6 million revolving line of credit, a $5.4 million commercial mortgage, and construction loans. Management is implementing cost-saving measures (headcount reductions, salary freezes, travel limits) and delaying construction projects to ensure compliance with debt covenants.
- Customer Concentration: Uncertainty regarding the Pfizer/Pharmacia merger delayed purchasing decisions by these major customers, negatively affecting product sales.
- Market Risk: The company is exposed to interest rate changes on variable-rate debt and foreign currency fluctuations, though management estimates a 10% adverse change would not be material.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the company's ability to maintain required ratios (EBITDA to debt, current assets to liabilities) given the recent loss and increased debt load.
- PKLB Merger Status: Confirm the status of the pending merger with PharmaKinetics Laboratories, Inc., as this is critical to the revised revenue outlook and future capital structure.
- Construction Project Viability: Assess the impact of the delayed West Lafayette construction project on future revenue generation and the necessity of the planned real estate sale to fund operations.
- Product Revenue Trends: Monitor the recovery of Culex product sales, which have declined significantly due to customer R&D spending cuts.
- Goodwill Impairment: Review the transitional impairment test results for goodwill under SFAS No. 142, particularly given the lower-than-expected revenue performance.